MoA studies of molecules derived from TB bacteria for the treatment of asthma

PeptInnoate发现，来自结核分枝杆菌(MTB)的蛋白质通过一种未知的作用机制，在体内(动物)和体外(人和动物)都意外地作为有效的抗炎剂发挥作用。已经成功地合成了MTB蛋白的多肽片段，并证明在这些系统中具有同等或增强的活性。该项目的重点是使用这些专利化合物来探索它们用于类固醇抵抗性哮喘的作用机制，以支持PeptInnoate(SME)的增长战略。我们将在人体免疫细胞和动物模型上使用创新的体外和体内技术。由此产生的机理认识将使PeptInnoate有可能成为第一个基于结核分枝杆菌蛋白质的独特性质开发新药的公司，使PeptInnoate成为一个有吸引力的许可合作伙伴，增加在英国的投资，并为患者提供治疗选择。

Peptinnovate have discovered that proteins derived from mycobacterium tuberculosis (mTB) unexpectedly act as potent anti-inflammatory agents both in vivo (animal) and in vitro (human and animal), via an unknown mechanism of action. Peptide fragments of the mTB protein have been successfully synthesised and shown to have equivalent or augmented activity in these systems. This project focuses on the use of these proprietary compounds to probe their mechanism of action for use in steroid resistant asthma supporting Peptinnovate's (SME) growth strategy. We will use innovative in vitro and in vivo techniques on human immune cells and in animal models. The resulting mechanistic understanding will allow Peptinnovate to be potentially the first to develop new medicines based on the unique properties of mTB proteins, making Peptinnovate an attractive licence partner, increasing UK investment, and providing therapeutic options to the patients.